Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)

eqs_en 
0 0 11.03.20
DGAP-Adhoc: Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
 

DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Miscellaneous
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)

11-March-2020 / 08:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)

Xlife Sciences AG tests a new therapy for the treatment of pneumonia caused by coronavirus in cooperation with the Institute of Virology and Immunology (IVI) of the Vetsuisse Faculty of the University of Bern in Switzerland. Advantages of the therapy are a fundamentally better biovariability and a broad target diversity. The necessary documents have successfully been submitted.

About Xlife Sciences AG

Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch

11-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Zürich
Switzerland
Phone: 0041 44 385 84 60
E-mail: [email protected]
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Listed: Regulated Unofficial Market in Munich
EQS News ID: 993771

 
End of Announcement DGAP News Service

993771  11-March-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=993771&application_name=news&site_id=sharewise

Xlife Sciences AG Stock

€42.20
-0.460%
Xlife Sciences AG shows a slight decrease today, losing €0.000 (-0.460%) compared to yesterday.

Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!